Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) has received a consensus rating of "Moderate

Algert Global LLC increased its stake in shares of Tyra Biosciences, Inc. (NASDAQ: TYRA) by 27.2% in

5AM Venture Management LLC bought a new position in Tyra Biosciences, Inc. (NASDAQ: TYRA) in the und

TYRA's dabogratinib has an upcoming readout in September 2026 that I think could validate its FGFR3

Tyra Biosciences (NASDAQ:TYRA) reported quarterly losses of $(0.69) per share which missed the analy

- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) - - Initial Ph2 d

Analysts change outlook on top Wall Street names. SNX, ORCL, EDU, ENS, SHOO, RH, have price target c

Top Wall Street analysts changed outlook on top names. See full list of rating changes on analyst ra

Wall Street analysts change outlook on top names, including upgrades/downgrades. Check our analyst r

B of A Securities analyst Geoff Meacham maintains Tyra Biosciences (NASDAQ:TYRA) with a Buy and r

-Collaboration aims to raise awareness of UTUC and the need for continued innovation for patients li

Wall Street analysts changed ratings on top names. Check our analyst ratings page for full updates.

Top Wall Street analysts upgraded STUB, PGNY, AMT, and BAP stocks and raised their price targets. Se

Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Analyst

Wolfe Research analyst Kalpit Patel initiates coverage on Tyra Biosciences (NASDAQ:TYRA) with a P

Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary te

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Tyra Biosciences (NASDAQ:TYRA) with

Tyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 Transcri

Tyra Biosciences (NASDAQ:TYRA) reported quarterly losses of $(0.64) per share which missed the analy

- Advanced "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC

CARLSBAD, Calif., May 7, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stag

Shares of Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) have been assigned an average reco

-Seasoned biopharmaceutical leader brings deep commercial and strategic expertise to support TYRA's

'Top Wall Street analysts changed outlook on top names. See all rating changes incl. upgrades, d

Guggenheim analyst Brad Canino initiates coverage on Tyra Biosciences (NASDAQ:TYRA) with a Buy ra

Canaccord Genuity analyst John Newman initiates coverage on Tyra Biosciences (NASDAQ:TYRA) with a

Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) Director Gilla Kaplan sold 14,295 shares of

Boone Capital added 398,482 shares of TYRA in the fourth quarter. The quarter-end position value ros

Piper Sandler analyst Allison Bratzel maintains Tyra Biosciences (NASDAQ:TYRA) with a Overweight

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001863127/000119312526091880/d48655d8k.htm

Tyra Biosciences (NASDAQ:TYRA) reported quarterly losses of $(0.57) per share which missed the analy

- Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC

Cantor Fitzgerald analyst Li Watsek initiates coverage on Tyra Biosciences (NASDAQ:TYRA) with a O

CARLSBAD, Calif., Feb. 23, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-st

CARLSBAD, Calif., Feb. 19, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-st

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Tyra Biosciences (NASDAQ:TYRA) with

Wedbush analyst Robert Driscoll maintains Tyra Biosciences (NASDAQ:TYRA) with a Outperform and ra

AquaBounty Technologies (NASDAQ: AQB - Get Free Report) and Tyra Biosciences (NASDAQ: TYRA - Get Fre

Robert More reported the sale of 246,871 shares on Nov. 21 as part of a Rule 10b5-1 trading plan. Th

Shares of Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) have been assigned an average reco

Shares of Skechers U.S.A., Inc. (NYSE: SKX) shares fell during Friday’s session after the company r